NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.14
+3.24%Year over year
Reported trailing growth
- Revenue
- -58.4%
- EBITDA
- -52.2%
- EBIT
- -56.7%
- EPS
- -32.2%
- Free cash flow
- -34.9%
- Operating cash flow
- -36.5%
Forward estimates
Based on analyst estimates
- Revenue
- +100.7%
- EBITDA
- +42.5%
- EPS
- +48.0%
Three-year CAGR
- Revenue
- +29.5%
- EBITDA
- -32.1%
- EBIT
- -34.1%
- Net income
- -36.6%
- EPS
- -5.9%
- Free cash flow
- -44.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of May 1, 2026